New Shire CEO Has Big Ophthalmology Plans; SARcode Sets The Stage
This article was originally published in The Pink Sheet Daily
Executive Summary
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.